Biweekly Combination of Trastuzumab, Docetaxel and Gemcitabine for HER2-Positive Metastatic Breast Cancer: Results of a Phase II GOIM Study
Laura Orlando, Saverio Cinieri(Ospedale A. Perrino), Ferdinando De Vita(University of Campania "Luigi Vanvitelli"), Salvatore Pisconti(Ospedale SS. Annunziata), Gianfranco Filippelli(Presidio Ospedaliero), Evaristo Maiello(Casa Sollievo della Sofferenza), Palma Fedele(Ospedale A. Perrino), Sandro Barni, Giuseppe Colucci(Roche (Switzerland)), Livio Blasi, Francesco Verderame(Ospedale Vincenzo Cervello), Francesco Giotta(Istituto Tumori Bari), Giovanni Pappagallo, Vito Lorusso, Ferdinando Riccardi(Ospedale Antonio Cardarelli), Nicola Gebbia(University of Palermo)
Cited by 3
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|347
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|285
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234